In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva, with a price target of $20.00. The company’s shares closed yesterday at $5.91.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Travere Therapeutics, and Madrigal Pharmaceuticals. According to TipRanks, Nash has an average return of 17.0% and a 47.38% success rate on recommended stocks.
Currently, the analyst consensus on Inventiva is a Strong Buy with an average price target of $19.20, which is a 224.87% upside from current levels. In a report released on September 29, Guggenheim also reiterated a Buy rating on the stock with a $13.00 price target.
Based on Inventiva’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $6.46 million and a GAAP net loss of $135.18 million. In comparison, last year the company earned a revenue of $16.54 million and had a GAAP net loss of $55.16 million
Read More on IVA:
Disclaimer & DisclosureReport an Issue
- Inventiva’s Strategic Focus and Financial Stability Drive Buy Rating Amid Promising Phase 3 Trial Progress
- Inventiva management to meet with Piper Sandler
- Inventiva Appoints Andrew Obenshain as CEO to Drive U.S. Market Expansion
- Inventiva SA Reports Progress and Challenges in 2025
- Inventiva S.A. Reports Significant Revenue Growth Amid Rising Losses
/AI%20(artificial%20intelligence)/AI%20engineer%20working%20on%20laptop%20by%20ART%20STOCK%20CREATIVE%20via%20Shutterstock.jpg)
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)